Tumor endothelial cells join the resistance

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 4787-4789

  Dudley, Andrew C ^a,b   Klagsbrun, Michael ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT;

ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; ENDOTHELIUM CELL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NOTE; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES;

EID: 68049120464     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0902     Document Type: Note

References (13)

1. Xiong Y, Sun H, Zhang W, et al. Presence of Human hepatocellular carcinoma tumorderived endothelial cells increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009; 15:4838-4846
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
3. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-286
4. Aird WC. Molecular heterogeneity of tumor endothelium. Cell Tissue Res 2009;335:271-281
5. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factortargeted therapy. Clin Cancer Res 2008;14:6371-6375
6. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15: 220-231
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239
8. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8: 592-603.
9. Dudley AC, Shih SC, Cliffe AR, Hida K, Klagsbrun M. Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer 2008;99:118-125 (Pubitemid 351920247)
10. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003;17:1159-1161
11. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005;123:1001-1011 (Pubitemid 41785416)
12. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-1202 (Pubitemid 30650733)
13. Stone EM. A very effective treatment for neovascular macular degeneration. N Engl J Med 2006;355:1493-1495 (Pubitemid 44511565)